146 related articles for article (PubMed ID: 37568060)
21. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
[TBL] [Abstract][Full Text] [Related]
22. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
23. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
24. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
Kuye IO; Frank RG; McWilliams JM
JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
[TBL] [Abstract][Full Text] [Related]
25. Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Guo JD; Keshishian A; Delinger R; Russ C; Rosenblatt L; Jiang J; Yuce H; Ferri M
J Thromb Thrombolysis; 2024 Jan; 57(1):1-10. PubMed ID: 37530955
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
27. Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Deitelzweig S; Keshishian A; Kang A; Jenkins A; Atreja N; Schuler P; Jiang J; Yuce H; Sun X; Lip GYH
Eur J Intern Med; 2023 Feb; 108():37-42. PubMed ID: 36456387
[TBL] [Abstract][Full Text] [Related]
28. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
29. Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Di Fusco M; Keshishian A; Delinger R; Ferri M; Jiang J; Seigel L; Yuce H; Guo JD
J Thromb Thrombolysis; 2023 Nov; 56(4):626-634. PubMed ID: 37530954
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
31. Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data.
Essien UR; Magnani JW; Chen N; Gellad WF; Fine MJ; Hernandez I
J Natl Med Assoc; 2020 Feb; 112(1):103-108. PubMed ID: 32035755
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
[TBL] [Abstract][Full Text] [Related]
33. Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016.
Alcusky M; McManus DD; Hume AL; Fisher M; Tjia J; Lapane KL
J Am Heart Assoc; 2019 May; 8(9):e012023. PubMed ID: 31046504
[TBL] [Abstract][Full Text] [Related]
34. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
35. Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Dhamane AD; Hernandez I; Di Fusco M; Gutierrez C; Ferri M; Russ C; Tsai WL; Emir B; Yuce H; Keshishian A
Am J Cardiovasc Drugs; 2022 May; 22(3):333-343. PubMed ID: 34671944
[TBL] [Abstract][Full Text] [Related]
36. Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation.
Alberts M; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Bookhart B; Kharat A
Adv Ther; 2023 May; 40(5):2339-2354. PubMed ID: 36947331
[TBL] [Abstract][Full Text] [Related]
37. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
38. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
40. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
